Travere Therapeutics, Inc. Q3 FY2026 earnings call

• CEO Transition: President and CEO Eric Dube announced his departure for December 1st, expressing strong confidence in incoming CEO Bradley and the executive team's ability to sustain momentum.
• Commercial Momentum: PhilSparry surpassed $200 million in quarterly net product sales for the first time. The company reaffirmed its long-term goal of achieving or exceeding $3 billion in annual PhilSparry sales by 2033.
• Patent Portfolio Strengthening: Travere secured a newly issued patent for methods of use in IgA nephropathy (expiring 2037) and received a notice of allowance for a patent application in FSGS, further extending IP protection.
• FSGS Launch Performance: Early launch metrics are strong, with high adoption trends, expanding prescriber bases, and approximately 40% of first-time FSGS prescribers being new to PhilSparry. Payer coverage has advanced rapidly, with most payers updating policies to include FSGS.
• Pipeline Advancements:
  • Pegzilarginase (PEG-2-Batinase): Enrollment is complete/substantial progress in the Phase III Harmony study for classical Homocystinuria (HCU), with top-line results expected in H2 2027.
  • Sivorebrutinib: Licensing agreement with Everest became effective; teams are preparing for U.S. IND submission by year-end to support dose evaluation and FDA engagement for immune-mediated kidney diseases.
• Clinical Data Updates: New data presented at ASN Kidney Week supports PhilSparry’s dual endothelin/angiotensin receptor blockade mechanism. SPARTAN trial data showed 75% of treatment-naive patients achieved complete remission over two years without immunosuppression.

Total U.S. net product sales reached $220.2 million, with total revenue at $224.6 million (including $4.4 million in licensing collaboration revenue). PhilSparry generated $200.2 million in U.S. net product sales, representing approximately 91% of total net product sales and marking a 120% year-over-year growth. This figure includes an estimated $8 million benefit from specialty pharmacy inventory buildup. IgA Nephropathy and FSGS indications contributed the remaining ~$20 million in net product sales.

• Full-Year Gross-to-Net Discounts: Management anticipates higher discounts in Q4, projecting full-year gross-to-net discounts for PhilSparry to be in the mid-20% range.
• Q4 Sales Impact: Q4 net sales are expected to be reduced by approximately $8 million as specialty pharmacies dispense existing inventory built up in Q3 back to normal levels.
• Long-Term Revenue Target: Maintained conviction in achieving or exceeding $3 billion in annual PhilSparry sales by 2033.
• Pipeline Timelines: Top-line results for Pegzilarginase (Harmony study) expected in H2 2027; US IND for Sivorebrutinib expected by year-end 2026.

• Market Competition and Sequencing: The evolving IgA nephropathy landscape involves new entrants (e.g., B-cell therapies). While management expects combination therapy, there is risk regarding physician sequencing habits and competition for nephrologist time.
• Seasonality and Variability: Quarterly patient start forms may experience variability due to summer seasonality and dynamic market conditions, though underlying demand remains strong.
• Access and Reimbursement: Although payer coverage for FSGS is advancing, delays in formulary inclusion could impact initial conversion rates, mitigated currently by free drug programs.
• Regulatory and Development Risks: Advancement of pipeline assets like Sivorebrutinib depends on successful IND submissions and favorable FDA feedback regarding development pathways.

Q: Analyst asked about the conversion rate and time-to-paid-script for FSGS relative to expectations and IgA nephropathy. / A: Peter Heerma stated that FSGS conversion is tracking faster than initially anticipated for the IgA launch, with nearly all payers now including PhilSparry on specific formularies. The time-to-conversion is approaching levels seen in IgA nephropathy, driven by rapid payer updates and strong prescriber enthusiasm.

Q: Analyst inquired about the strategic sequencing of treatments in IgA nephropathy, specifically how PhilSparry fits alongside emerging B-cell therapies and RAS inhibitors. / A: Eric Dube outlined a dual-segment strategy: for the 30% higher-risk patients, B-cell therapies may replace steroids but will likely be combined with PhilSparry for kidney protection. For the 70% lower-risk patients, PhilSparry is increasingly used earlier as a foundational kidney-targeted therapy, often before RAS inhibitors, aligning with KDIGO guidelines for early intervention.

Q: Analyst questioned whether sequential growth in IgA nephropathy reflects seasonality versus pent-up demand, and if adding PhilSpari after B-cell therapies faces payer barriers. / A: Peter Heerma acknowledged summer seasonality but noted strong Q3 performance. He emphasized that B-cells are primarily added on top of PhilSparry rather than replacing it. There is no significant payer pushback for this combination, as PhilSparry remains the preferred kidney-targeted medicine, especially in the >70% of patients with proteinuria <1.5g/g who are largely treatment-naive to other branded agents.

Q: Analyst asked for clarity on pediatric utilization in FSGS and whether access/logistics differ from adults. / A: Peter Heerma reported that pediatric patients comprise up to 10% of starts, consistent with clinical trial data. He confirmed there is no difference in access, gross-to-net dynamics, or REMS logistics between pediatric and adult patients, citing rapid national account team progress with payers.

Q: Analyst sought details on the next steps for Sivorebrutinib, particularly regarding membranous nephropathy and biomarker discussions with the FDA. / A: Jula Inrig explained that the immediate priority is opening the US IND to generate bridging PK/PD data and align with the FDA on global development plans. While primary membranous nephropathy is a priority indication due to preclinical data, feasibility assessments are ongoing for FSGS and minimal change disease. Biomarker analysis for accelerated approval is still in early stages.